A patient study of the topical formulation of ZPL-521 for psoriasis
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2016
At a glance
- Drugs ZPL 5212372 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2016 According to a company media release, the company anticipates data from this study in the first half of 2017.
- 08 Jul 2015 Patients and trial focus are assumed.
- 08 Jul 2015 New trial record